MedTrace Logo

Transperineal Laser Ablation for Low- and Intermediate Risk Prostate Cancer: a Single Cohort Analysis

NCT05584787 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-01-10

No results posted yet for this study

Summary

The goal of this prospective study is to test the efficacy of Echolaser transperineal focal therapy in patients with low- and intermediate risk prostate cancer. The main question it aims to answer are: 1. short and intermediate term oncological outcomes after laser focal therapy, 2. functional outcomes and quality of life after treatment. Participants affected by low risk prostate cancer will undergo trans perineal laser focal therapy. Multiparametric prostate MRI will be perform after 3 and 12 months for oncological control. Re-fusion biopsy will be perform after 12 months. Functional outcomes and quality of life will be assess at 3, 6 and 12 months.

Conditions

Interventions

PROCEDURE

Soractelite Echolaser Transperineal focal laser ablation

US/MRI fusion laser ablation of low- and intermediate risk prostate cancer

Sponsors & Collaborators

  • Elesta S.R.L.

    collaborator INDUSTRY

  • San Carlo di Nancy Hospital

    lead OTHER

Principal Investigators

  • Pierluigi Bove, MD · San Carlo di Nancy Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2024-02-29
Completion
2024-03-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05584787 on ClinicalTrials.gov